In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).
Age over 18 years old, gender not limited.
The patient voluntarily joined this study and signed informed consent
ECOG score is 0 or 1
Expected survival period ≥ 2 years.
Received systemic anti-tumor therapy 4 weeks before starting the study treatment
The toxicity and/or complications of previous anti-tumor treatments have not recovered to NCI-CTCAE ≤ 1 level
Subjects known or suspected to have interstitial pneumonia
Individuals with any active, known or suspected autoimmune diseases